Focused on overcoming resistance in the most aggressive and difficult-to-treat tumors
Redefining What’s Possible in Cancer Treatment
Our Mission
A Mission Driven by Urgency
Tactical Therapeutics is dedicated to developing breakthrough therapies for patients facing the most aggressive and treatment-resistant cancers. Our mission is to overcome the biological barriers that limit current therapies and deliver meaningful, lasting outcomes where few options exist.
We are driven by a singular focus: advancing science that translates into real hope for patients and their families.
A Clinical-Stage Biopharmaceutical Company
Tactical Therapeutics is a clinical-stage biotechnology company advancing a novel therapeutic platform designed to target glioblastoma (GBM) and other resistant solid tumors.
Our work centers on Carboxyamidotriazole Orotate (CTO), a best-in-class oral therapy engineered to penetrate the brain and disrupt calcium signaling pathways that drive tumor growth and resistance.
By addressing multiple oncogenic mechanisms simultaneously, we aim to shift the treatment paradigm for cancers that have historically been among the most difficult to treat.
Since 2005
At Tactical Therapeutics, she is inventor of 8 US patents and over 75 international patents.
Prior to founding her companies, Dr. Karmali worked at leading law firms in New York (Hopgood & Calimafde, Pennie & Edmonds, Bryan Cave and Stroock, Stroock & Lavan), and specialized in practice areas of Intellectual Property including Prosecution, Transactions and Litigation involving drug patent infringement cases. Dr. Karmali worked on precedent setting cases including Glaxo v. Novopharm and Eli Lilly v. Barr Labs.
During 1984 to 1990, Dr. Karmali was an Associate Professor of Nutrition at Cook College, Rutgers University in New Brunswick, NJ, supervised Ph. D and MS candidates and held an Adjunct Associate member position at Memorial Sloan-Kettering Cancer Center (as Principal Investigator of a Phase I Breast Cancer Prevention Trial).
From 1980 to 1984, Dr. Karmali worked with Dr. Robert A. Good, President, at Memorial Sloan-Kettering in Department of Cellular Engineering, Immunology & Cancer Therapy, in New York. Her research program focused on the role of eicosanoids and polyunsaturated fatty acids in cancer and in autoimmune diseases. Dr. Karmali has authored over 100 scientific publications
Dr. Karmali’s work on Omega-3 Fatty acids and cyclo-oxygenase -2 (COX-2) in cancer was featured on the Cover of Cancer Research in the December 1997 issue. She received the Lifetime Achievement Award from Marquis Who’s Who in 2017.
Dr. Karmali earned her M.B.A (2007) and J.D (1993) at Rutgers University, Newark NJ. She is a Registered Patent Agent and a Certified Licensing Professional. She is a member of AACR, ACS, ASCO, AIPLA, ABA and LES.
Dr. Karmali earned her Ph. D in Biochemistry at University of Newcastle Upon Tyne, UK, the M.Sc. in Nutrition at Aberdeen University, UK and BSc in Chemistry & Biochemistry at Makerere University, Uganda.
Our Approach
Targeting the Root of Resistance
Traditional cancer therapies often fail due to the complex and adaptive nature of tumor biology. Tactical Therapeutics is taking a different approach by targeting non-voltage-dependent calcium (ca)²⁺ signaling, a critical driver of multiple cancer, genomic, epigenetic, and immunologic, pathways.
Advancing Hope Where It’s Needed Most
For patients diagnosed with aggressive cancers like glioblastoma, treatment options are limited and outcomes remain poor. Tactical Therapeutics exists to challenge that status quo.
By combining scientific innovation with clinical focus, we are working to deliver therapies that not only extend survival but improve quality of life.
This strategy enables us to:
Impact several oncogenic processes at once
Overcome resistance mechanisms that limit standard treatments
Deliver therapy directly to the brain through effective blood-brain barrier penetration
The Future of Cancer Treatment Starts Here
Tactical Therapeutics is building a future where even the most resistant cancers can be treated effectively. Through innovation, precision, and relentless focus, we are advancing therapies designed to make a lasting impact.
Management Team
Financial Services
Presti & Naegle LLC and RSM LLC (2005- present)
Regulatory Services
Cardinal Health Services (2014 -present)
Medical Officer
Dr. Linda Bavisotto, Part-Time (2014- 2023)
Scientific Advisors and Consultants
Dr. Roger Stupp, Chief, Neuro-oncology, Professor of Neurosurgery, Medicine and Neurology, Feinberg School of Medicine at Northwestern University, Chicago, IL
Dr. Robert Aiken, Co-Director Glasser Brain Cancer Center, Summit, NJ
Dr. Stephen Byrn, Medicinal Chemistry, Purdue University, West Lafayette, IN. Consultant, Medicinal Chemistry, Manufacturing, Formulation.
Dr. Greg Gorman, Pharmaceutical Sciences, Director, Samford Univ School of Pharmacy, Birmingham, AL. Consultant, Bioanalytic methods of analysis, drug metabolism, drug-drug interactions, and pharmacokinetics for small molecules. (2005-present)
Dr. Yulia Maxuitenko, Auburn Univ Harrison College of Pharmacy, Auburn, AL. Consultant, Pre-clinical drug development for cancer drugs in animal models. (2005-present)
Mr. Ravi Badge, Technology And Cyber Security, NJ Cyber Solutions, CMIT Solutions Piscataway, NJ